| A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors | Frankfurt am Main | Phase II | rekrutiert |
| A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors | Berlin | Phase I | rekrutiert |
| A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) | Aachen, Trier, Saarbrücken | Phase III | rekrutiert |
| DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrol | Berlin, Chemnitz, Dessau | Phase III | rekrutiert |
| European Collaborative Multicenter Observational Study: Modular Treatment With PMMR and Targeted | Essen | — | rekrutiert |
| Immunotherapy-related CRP Kinetics in Metastatic Gynecological Malignancies | Tübingen | — | rekrutiert |
| NIS to Examine the Effectiveness and Safety of Durvalumab and Olaparib in Patients With Endometr | Amberg, Bad Nauheim, Bautzen | — | rekrutiert |
| Performance of SYMMCORA® vs. V-Loc® Suture Material in Patients Undergoing Laparoscopic Total Hy | Frankfurt am Main | — | rekrutiert |
| Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid T | Berlin, Essen, Freiburg im Breisgau | Phase I / Phase II | rekrutiert |
| Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer | Amberg, Chemnitz, Dresden | Phase III | rekrutiert |
| Registry Platform Ovarian and Endometrial Cancer | Multiple Locations | — | rekrutiert |
| Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Can | Aachen, Berlin, Kempten (Allgäu) | Phase II | rekrutiert |
| Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Adv | Berlin, Essen, Hannover | Phase II | rekrutiert |
| Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+ | Detmold, Frankfurt am Main | Phase III | rekrutiert |
| Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice | Lemgo, Hamburg | Phase III | rekrutiert |
| The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation | Heidelberg, Augsburg, Hamburg | Phase I / Phase II | rekrutiert |